| DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2296 | 2015 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ... New England Journal of Medicine 378 (19), 1789-1801, 2018 | 1804 | 2018 |
| Olaparib for metastatic castration-resistant prostate cancer J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 382 (22), 2091-2102, 2020 | 1769 | 2020 |
| Enzalutamide with standard first-line therapy in metastatic prostate cancer ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... New England Journal of Medicine 381 (2), 121-131, 2019 | 1263 | 2019 |
| [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ... The Lancet Oncology 19 (6), 825-833, 2018 | 976 | 2018 |
| Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study GV Long, V Atkinson, S Lo, S Sandhu, AD Guminski, MP Brown, ... The Lancet Oncology 19 (5), 672-681, 2018 | 905 | 2018 |
| Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ... Annals of Oncology 28 (2), 368-376, 2017 | 816 | 2017 |
| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 657 | 2021 |
| The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial SK Sandhu, WR Schelman, G Wilding, V Moreno, RD Baird, S Miranda, ... The lancet oncology 14 (9), 882-892, 2013 | 621 | 2013 |
| Survival with olaparib in metastatic castration-resistant prostate cancer M Hussain, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 383 (24), 2345-2357, 2020 | 604 | 2020 |
| Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ... The Lancet Oncology 21 (1), 162-174, 2020 | 575 | 2020 |
| An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer ML Burr, CE Sparbier, KL Chan, YC Chan, A Kersbergen, EYN Lam, ... Cancer cell 36 (4), 385-401. e8, 2019 | 457 | 2019 |
| Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Y Loriot, D Bianchini, E Ileana, S Sandhu, A Patrikidou, C Pezaro, ... Annals of oncology 24 (7), 1807-1812, 2013 | 417 | 2013 |
| Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer HI Scher, G Heller, A Molina, G Attard, DC Danila, X Jia, W Peng, ... Journal of clinical oncology 33 (12), 1348-1355, 2015 | 403 | 2015 |
| Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition J Goodall, J Mateo, W Yuan, H Mossop, N Porta, S Miranda, ... Cancer discovery 7 (9), 1006-1017, 2017 | 396 | 2017 |
| Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor LJ Barber, S Sandhu, L Chen, J Campbell, I Kozarewa, K Fenwick, ... The Journal of pathology 229 (3), 422-429, 2013 | 384 | 2013 |
| Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes J Violet, P Jackson, J Ferdinandus, S Sandhu, T Akhurst, A Iravani, ... Journal of Nuclear Medicine 60 (4), 517-523, 2019 | 364 | 2019 |
| Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a … AMM Eggermont, M Kicinski, CU Blank, M Mandala, GV Long, V Atkinson, ... JAMA oncology 6 (4), 519-527, 2020 | 351 | 2020 |
| UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas SQ Wong, K Waldeck, IA Vergara, J Schröder, J Madore, JS Wilmott, ... Cancer research 75 (24), 5228-5234, 2015 | 339 | 2015 |
| Envisioning the future of early anticancer drug development TA Yap, SK Sandhu, P Workman, JS De Bono Nature Reviews Cancer 10 (7), 514-523, 2010 | 325 | 2010 |
